Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Arctic Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Christer Valderhaug

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	6.1yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

We're Keeping An Eye On Arctic Bioscience's (OB:ABS) Cash Burn Rate

Aug 20

We're Hopeful That Arctic Bioscience (OB:ABS) Will Use Its Cash Wisely

Jul 08

Here's Why We're Not Too Worried About Arctic Bioscience's (OB:ABS) Cash Burn Situation

Apr 09

CEO

Christer Valderhaug (52 yo)

no data

Görev süresi

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harald Nordal	Co-Founder & Chairman	9yrs	Veri yok	Veri yok
Christer Valderhaug	Chief Executive Officer	no data	Veri yok	0.016% NOK 8.1k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.5yrs	Veri yok	1.81% NOK 929.2k
Jone Slinning	Chief Financial Officer	2.5yrs	Veri yok	0.052% NOK 26.7k
Per Sæbo	Chief Operating Officer	12.3yrs	Veri yok	0.090% NOK 46.3k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	Veri yok	Veri yok
Steffen Eidal	Senior Vice President of Sales & Marketing	2.5yrs	Veri yok	Veri yok
Yuming Feng	Executive Vice President of Global Business Development	6.1yrs	Veri yok	Veri yok
Runhild Gammelsæter	Global Medical Director	5.2yrs	Veri yok	0.14% NOK 70.2k

6.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: ABS 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Harald Nordal	Co-Founder & Chairman	9yrs	Veri yok	Veri yok
Jostein Dalland	Independent Board Member	4.6yrs	Veri yok	Veri yok
Tore Andreas Tonseth	Board Member	3.8yrs	Veri yok	Veri yok
Asbjorn Solevagseide	Board Member	5.5yrs	Veri yok	Veri yok
Jan Vartdal	Board Member	9yrs	Veri yok	4.1% NOK 2.1m
Per Eggesbo	Board Member	8.8yrs	Veri yok	Veri yok
Hu Cao	Board Member	3.7yrs	Veri yok	Veri yok
Marita Holstad	Director	3.8yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Arctic Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Global Medical Director recently bought kr160k worth of stock

Chief Executive Officer recently bought kr299k worth of stock

Less than half of directors are independent

Global Medical Director recently bought kr101k worth of stock

Less than half of directors are independent

Board Member recently bought kr220k worth of stock

Recent updates

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Share price stability

New major risk - Financial position

Consensus revenue estimates fall by 28%

We're Keeping An Eye On Arctic Bioscience's (OB:ABS) Cash Burn Rate

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

New major risk - Share price stability

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Consensus EPS estimates upgraded to kr1.74 loss, revenue downgraded

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings: Revenues miss analyst expectations

Global Medical Director recently bought kr160k worth of stock

Chief Executive Officer recently bought kr299k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Price target decreased to kr15.00

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Consensus forecasts updated

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

We're Hopeful That Arctic Bioscience (OB:ABS) Will Use Its Cash Wisely

Global Medical Director recently bought kr101k worth of stock

Less than half of directors are independent

Board Member recently bought kr220k worth of stock

Here's Why We're Not Too Worried About Arctic Bioscience's (OB:ABS) Cash Burn Situation

Full year 2021 earnings: Revenues miss analyst expectations

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

Board Member recently bought kr498k worth of stock

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş